As the COVID-19 pandemic rages on, vaccines offer a glimmer of hope in these dark times. The world has moved swiftly in unison to develop COVID-19 vaccines, with India leading from the front in terms of COVID-19 vaccine production and supplying it to the rest of the world.
India had approved the indigenously developed COVAXIN by Bharat Biotech and COVISHEILD (AstraZeneca) manufactured by Serum Institute of India (SII) on January 3, 2021. The Drug Controller General of India (DGCI) had approved the vaccines on the basis of ‘restricted’ use in an ‘emergency’ situation, with the vaccination drive commencing on January 16, 2021. The Sputnik V developed by Gamaleya Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) received the nod on April 12, 2021. The centre procured 1.10 crore doses of COVISHEILD at the cost of Rs 200/dose (excluding taxes) and 55 lakh doses of COVAXIN. The cost of 38.5 lakh doses of COVAXIN was Rs 295/ dose (excluding taxes) but the company provided 16.5 lakh doses of COVAXIN free of cost to the central government reducing the cost to Rs 206/dose. The central government was able to procure the vaccines at this price by putting a price cap on the vaccine. The cost of Sputnik V hasn’t been announced as yet. This is a two-dose vaccine that costs approximately $10 per dose in the global market.
Denne historien er fra BioSpectrum Asia May 2021-utgaven av BioSpectrum Asia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra BioSpectrum Asia May 2021-utgaven av BioSpectrum Asia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.